Cogent Biosciences, Inc.
COGTNext catalyst
bezuclastinib
Advanced Systemic Mastocytosis (AdvSM)
Get an email about COGT's next catalysts
Track Cogent Biosciences (COGT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 1 past
COGT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.57 | FQ end Sep/2026 | Call: tbd
FDA PDUFA Date bezuclastinib
Extracted from SEC filing: EX-99.1
SourceCGT4859 Phase 2 Est. Readout
Primary completion for CGT4859 trial (NCT06777316) in Intrahepatic Cholangiocarcinoma (Icc)
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
CGT9486
Gastrointestinal Stromal Tumors
CGT9486 plus sunitinib
Advanced Gastrointestinal Stromal Tumors
CGT4859
Intrahepatic Cholangiocarcinoma (Icc)
Bezuclastinib in combination with sunitinib
Gastrointestinal Stromal Tumors
Bezuclastinib Tablets (Formulation B)
SSM
bezuclastinib
Advanced Systemic Mastocytosis (AdvSM)
Pexidartinib
Gastrointestinal Stromal Tumors
Bezuclastinib Tablets (Formulation A)
SSM
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CGT9486 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
CGT9486 plus sunitinib | Phase 3 | Advanced Gastrointestinal Stromal Tumors | - | - |
CGT4859 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | - | - |
Bezuclastinib in combination with sunitinib | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Bezuclastinib Tablets (Formulation B) | Phase 2 | SSM | - | - |
bezuclastinib | Phase 2 | Advanced Systemic Mastocytosis (AdvSM) | - | - |
Pexidartinib | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Bezuclastinib Tablets (Formulation A) | Phase 2 | SSM | - | - |
Frequently asked questions
What is in Cogent Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Cogent Biosciences, Inc.'s (COGT) pipeline across Phase 3, Phase 2. Its lead program is bezuclastinib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cogent Biosciences, Inc.'s next FDA catalyst?→
Cogent Biosciences, Inc.'s (COGT) next tracked catalyst is a PDUFA date expected Dec 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track COGT biotech catalysts?→
Add COGT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cogent Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.